Osteopore (ASX:OSX) Retained Earnings: A$-21.72 Mil (As of Dec. 2025)


What is Osteopore Retained Earnings?

Osteopore ASX:OSX -20.00% Retained Earnings is A$-21.72 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Osteopore's retained earnings for the quarter that ended in Dec. 2025 was A$-21.72 Mil.

Osteopore's quarterly retained earnings declined from Dec. 2024 (A$-18.07 Mil) to Jun. 2025 (A$-19.68 Mil) and declined from Jun. 2025 (A$-19.68 Mil) to Dec. 2025 (A$-21.72 Mil).

Osteopore's annual retained earnings declined from Dec. 2023 (A$-14.71 Mil) to Dec. 2024 (A$-18.07 Mil) and declined from Dec. 2024 (A$-18.07 Mil) to Dec. 2025 (A$-21.72 Mil).

Osteopore  (ASX:OSX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Osteopore Retained Earnings Historical Data

* Premium members only.

The historical data trend for Osteopore's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Osteopore Retained Earnings Chart

Osteopore Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -7.95 -10.90 -14.71 -18.07 -21.72

Osteopore Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.71 -16.33 -18.07 -19.68 -21.72

Osteopore Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of A$-21.72 Mil mean?
Osteopore (ASX:OSX) has a Retained Earnings of A$-21.72 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Osteopore and its competitors.
Is Osteopore's Retained Earnings too high?
Osteopore's current Retained Earnings is A$-21.72 Mil.
How does Osteopore's Retained Earnings compare to ISRG and BDX?
Osteopore's Retained Earnings of A$-21.72 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Osteopore and its competitors. Osteopore's current Retained Earnings is A$-21.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Retained Earnings is A$-21.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current Retained Earnings is A$-21.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Osteopore Business Description

Address 2 Tukang Innovation Grove, No. 09-06 and 07, JTC MedTech Hub, Singapore, SGP, 618305
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.